Rise and shine. Another day is on the way. And as usual, this promises to be a busy one, especially since we hope to meet with a source or two amid the usual scramble of deadlines. We envision, therefore, a day filled with several cups of stimulation. What better way to ensure productivity, though? We trust you can relate, so hoist a cup and dig in to a few tidbits. Have a great day and keep us in mind if you hear anything interesting...
Bayer Seeks EU Approval For Xarelto For Pulmonary Embolism (Dow Jones)
Could Autism Be Reversed With A Pill? (The Boston Globe)
New Teva CEO Undertakes R&D Review (Ha'aretz)
Roche First-Quarter Sales Hurt By Pricing (Bloomberg News)
Watson May Buy Actavis By End Of April (Reuters)
Gilead Bets On Hepatitis C Data To Justify Pharmasset Deal (Bloomberg News)
Is The New Purdue Sleeping Pill Promising Or Perilous? (ABC News)
MMRV Vaccine Not Tied To Seizures In Older Kids (Reuters)
Azerbaijan Bans Drugs Without Azeri On Labeling (Trend)
EDITOR'S NOTE: Please check this post for updates throughout the day
road pic thx to NicholasT on flickr
1 Comment
Since zolpidem can be used as a sex enhancer, the 2AM sublingual pop of Intermezzo is just what Dr T Woods ordered.